指南与共识甲状腺与浅表US

Hürthle细胞学结节临床病理结局与甲状腺结节应用(TNAPP)超声推荐意见的回顾性研究

A Retrospective Study of Clinicopathologic Outcomes of Nodules With Hürthle Cell Cytology and the Thyroid Nodule App (TNAPP) Ultrasound Recommendations.
指南 / 共识 · Endocr Pract · 2022-03-17

回顾性分析59个Bethesda III/IV级Hürthle细胞为主结节,按TNAPP超声分类1/2/3级(低/中/高风险)记录管理建议并与手术病理对照。超声分类1级结节均为良性,2级和3级分别有30%和40%为恶性。作者认为TNAPP是Hürthle细胞学结节超声评估的有用临床工具。

要点

  • TNAPP超声1级(低风险)Hürthle细胞结节本组均为良性。
  • 超声2级(中风险)结节30%恶性,3级(高风险)结节40%恶性。
  • ThyroSeq检测29例中22例(76%)阳性,其中7例恶性。

核心结论

  • 这项初步研究提示,TNAPP是Hürthle细胞学甲状腺结节超声评估的有用临床工具。

研究设计与样本

  • 回顾性研究,纳入2017年至2021年间接受手术、Bethesda III级(意义未定的异型性伴Hürthle细胞)或Bethesda IV级(可疑Hürthle细胞肿瘤)细胞学结节,共57例患者59个结节,依据结节特征分配TNAPP超声分类1、2、3级(分别为低、中、高风险)并记录临床管理建议,与组织学确诊诊断比较。

诊断标准与关键数值

  • 59个结节中,TNAPP超声分类1级(低风险/低可疑)4个、2级(中风险/中可疑)40个、3级(高风险/高可疑)15个;超声分类1级结节均为良性,超声分类2级结节30%为恶性,超声分类3级结节40%为恶性;接受ThyroSeq分子标记检测的患者中29例有22例(76%)阳性,提示中或高恶性风险,其中7例为恶性。

临床应用与阅片要点

  • 对Hürthle细胞为主的Bethesda III/IV级结节,可按TNAPP超声分类记录风险等级并对应管理建议,分类1级本组均为良性,2级和3级恶性比例分别为30%和40%。

局限性

  • 原文称本研究为初步研究(preliminary study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Hürthle cells are a common finding on thyroid fine-needle aspiration, but when they are the predominant cytology, they represent a difficult diagnostic challenge. The Thyroid Nodule App (TNAPP) is a new, publicly available web application utilizing ultrasound (US) features based on the updated 2016 American Association of Clinical Endocrinologists clinical practice guidelines for thyroid nodule management. This pilot study was performed to assess the TNAPP recommendations and surgical pathology outcomes of Hürthle cell-predominant thyroid nodules.

METHODS: A retrospective review of nodules with Bethesda III (atypia of undetermined significance with Hürthle cells) or Bethesda IV (suspicious for Hürthle cell neoplasm) cytology, for which surgery was performed between 2017 and 2021, was conducted. TNAPP US categories 1, 2, and 3 (low, intermediate, and high risk, respectively) were assigned based on nodule characteristics, and clinical management recommendations were recorded. Results were compared with histology-proven diagnoses.

RESULTS: Fifty-nine nodules in 57 patients where surgical pathology was available were analyzed with the TNAPP algorithm. Of the 59 nodules, 4 were US category 1 (low risk/suspicion), 40 were US category 2 (intermediate risk/suspicion), and 15 were US category 3 (high risk/suspicion). All US category 1 nodules were benign, while 30% of the US category 2 and 40% of the US category 3 nodules were malignant. Of the patients who had molecular marker testing with ThyroSeq, 22 out of 29 (76%) were positive, indicating either an intermediate or high risk of malignancy, 7 of which were malignant.

CONCLUSION: This preliminary study suggests that TNAPP is a useful clinical tool for sonographic assessment of thyroid nodules with Hürthle cell cytology.

来源:Endocr Pract,查看原文。版权归原作者所有。

引用

  1. Spagnuolo, Tierney, Laver, et al. A Retrospective Study of Clinicopathologic Outcomes of Nodules With Hürthle Cell Cytology and the Thyroid Nodule App (TNAPP) Ultrasound Recommendations. Endocr Pract. 2022. PMID: 35307577. doi:10.1016/j.eprac.2022.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。